Squarepoint Ops LLC Karuna Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $509,274 - $1.01 Million	-3,163 Reduced 70.43%	1,328 $420,000
Q2 2023 Aug 14, 2023	BUY	$176.32 - $240.22 $791,853 - $1.08 Million	4,491 New	4,491 $973,000
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $1.23 Million - $1.52 Million	-6,411 Reduced 28.03%	16,465 $3.24 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $2.83 Million - $6.35 Million	22,876 New	22,876 $5.15 Million
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $276,174 - $343,499	-2,729 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$107.45 - $135.95 $293,231 - $371,007	2,729 New	2,729 $311,000
Q1 2021 May 17, 2021	SELL	$95.46 - $133.08 $1.43 Million - $1.99 Million	-14,982 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$75.23 - $109.23 $579,421 - $841,289	-7,702 Reduced 33.95%	14,982 $1.52 Million
Q3 2020 Nov 16, 2020	SELL	$71.31 - $109.74 $2.55 Million - $3.93 Million	-35,814 Reduced 61.22%	22,684 $1.75 Million
Q2 2020 Aug 14, 2020	BUY	$62.14 - $117.21 $3.22 Million - $6.07 Million	51,818 Added 775.72%	58,498 $6.52 Million
Q1 2020 May 15, 2020	BUY	$60.41 - $115.92 $403,538 - $774,345	6,680 New	6,680 $481,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.